C-MAS9alternative splicing modulation, CLK/DYRK inhibition, Wnt pathway modulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize standard outcomes to evaluate the safety and efficacy of lorecivivint.
This study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors. The study will evaluate the safety, tolerability, PK, and preliminary anti-tumor efficacy of SM08502 administered orally (PO), once daily (QD), following a 5 days on 2 days off treatment schedule in combination with chemotherapy or hormonal therapy. Alternative dosing schedules may be explored in Part 1 if necessary. The recommended Part 2 dose and schedule for each combination will then be further evaluated in the Part 2 expansion. Dosing will occur in 21- or 28-day cycles (depending on the combination partner) and treatment with SM08502 will continue within each subject unless treatment is discontinued due to toxicity, disease progression, initiation of a new anti-neoplastic therapy, withdrawal of consent, the Sponsor terminates the study, or the subject no longer meets retreatment criteria.
This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.
This study will be an open-label, parallel-arm study to determine if a prior intra-articular (IA) injection of lorecivivint (LOR) affects the safety, tolerability, and/or pharmacokinetics (PK) of a subsequent IA injection of the corticosteroid triamcinolone acetonide (TA) into the same knee, and to determine if a prior IA injection of TA affects the safety or tolerability of a subsequent IA injection of LOR into the same knee.
Study OA-07 was a randomized, double-blind, placebo-controlled, Phase 3, multicenter, 2-year clinical trial that enrolled subjects from the recently completed Study OA-11 (NCT03928184). The first 48 weeks of OA-07 the trial was placebo-controlled with subjects receiving the same randomized treatment received in OA-11. Investigators, research staff and subjects remained blinded to treatment allocation. At Week 48, all subjects were administered LOR in the open-label portion of the trial.
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize patient reported outcomes (PROs) to evaluate the safety and efficacy of lorecivivint.
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize radiographs and patient reported outcomes (PROs) to evaluate the safety and efficacy of lorecivivint.
The purpose of this study was to evaluate the safety and efficacy of lorecivivint (LOR) injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects. Efficacy was primarily evaluated via magnetic resonance imaging (MRI).
The primary purpose of this phase 2, placebo-controlled, double-blind, parallel group study was to provide an initial safety evaluation of two intra-articular (IA) injections of SM04690 (each at the dose of 0.07mg per 2mL injection) approximately six months apart into the target knee of moderately to severely symptomatic osteoarthritis (OA) subjects. Subjects who completed this 52-week long study were invited to enter the extension phase for an additional 52 weeks of treatment.
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic alopecia (AGA) subjects.
This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. The study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part 1A). Alternative dosing schedules will be explored in Part 1B and the recommended Part 2 dose and schedule will be further evaluated in Part 2. Subjects will participate in a screening period of up to 14 days. Dosing in 28-day cycles will continue within each subject, unless treatment is discontinued due to toxicity, disease progression, initiation of a new anti-neoplastic therapy, withdrawal of consent, the Sponsor terminates the study, or the subject no longer meets retreatment criteria. Approximately 10 subjects enrolled in Part 2, irrespective of the tumor type, will be included in a food effect substudy to assess the preliminary effect of a high-fat, high-calorie meal on the PK of SM08502. Subjects participating in the food effect substudy will continue on study and complete assessments as per the Part 2 schedule and receive SM08502 at the recommended Part 2 dose (or another previously assessed dose level and schedule).
This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
SM04690-DDD-01 is a Phase 1, open-label, dose escalation study. SM04690 Injectable Suspension will be administered via a single intradiscal injection to subjects with degenerative disc disease (DDD) under fluoroscopic guidance. Groups of 6 subjects will be enrolled in successive cohorts. Subjects will participate in a 6 month follow-up period. Clinic visits will be Screening, Treatment Visit Day 1, and Follow-up Visit Days 2, 15, 28, 60, 90, 135, and 180.
This phase 2 study is a placebo-controlled, double-blind, parallel group study of four concentrations of SM04690 (0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected intraarticularly (IA) into the target knee joint of subjects with moderately to severely symptomatic osteoarthritis (OA). Based on previous studies of SM04690, key phenotypes of laterality (unilateral vs bilateral) as well as chronic pain (as measured by the Widespread Pain Index) were identified as confounding variables impacting the overall assessment of both radiologic and clinical efficacy outcomes. The design of SM04690-OA-04 is based upon previous study designs while assessing strategies to combat the confounding impact of laterality and chronic pain. To evaluate the effect of IA vehicle injection on patient-reported outcomes (PRO) such as pain, stiffness, and function in OA, this study also includes one cohort that receives a 2 mL IA injection of vehicle (placebo), and one cohort that receives a sham injection (i.e., a needle stick with 0 mL vehicle injected).
This study is a single-center, randomized, single-blind, placebo-controlled, multiple ascending dose study of SM04755 solution applied topically once daily for 14 days to intact skin overlying the inner thigh of healthy subjects at an estimated body surface area (BSA) of 80 cm\^2. Dosing cohorts will consist of 8 subjects who will be randomized 3:1 (SM04755:placebo).
This long-term extension study is designed to monitor the long-term safety, tolerability, and efficacy of treatment of SM04690 or placebo previously injected in the target knee joints of subjects with moderately to severely symptomatic osteoarthritis (OA) from a Samumed-sponsored SM04690-OA phase 2 or phase 3 study. No additional SM04690 or placebo therapy will be administered in this study.
The purpose of this study is to assess the efficacy, safety, and tolerability of three different strengths of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects.
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer. The study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SM04755 administered orally. Upon determination of the maximum tolerated dose (MTD), expansion cohorts may be enrolled.
The purpose of this study is to find the optimal dose of SM04690 that can be safely given by intra-articular injection into the target knee joint of subjects with moderate to severe osteoarthritis.
SM04646-IPF-03 is a Phase 2a, multi-center, open-label study evaluating the safety and efficacy of a single inhaled, nebulized dose of SM04646 solution over a 12-week treatment regimen in subjects with mild to moderate IPF. A total of approximately 24 subjects will be enrolled in the study (approximately 12 subjects into the "non-bronchoalveolar lavage \[BAL\]" arm and approximately 12 subjects into the "BAL" arm). Subjects that currently do not require, have failed to tolerate, or have opted not to have treatment with pirfenidone or nintedanib will have the option of participation in the "BAL" arm or participation in the "non-BAL" arm. Subjects currently receiving treatment with pirfenidone or nintedanib must be on stable treatment for a minimum of 12 weeks prior to the Screening Visit. Subjects currently on treatment with pirfenidone or nintedanib may participate in the "non-BAL" arm only. Eligible subjects will participate in a treatment period of 12 weeks and a follow-up period of 12 weeks. The treatment dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day "on" week.
Arman Oruc Lawyer / Attorney | Goodwin Skip to main content Goodwin Expertise People Careers Legal Paralegal Science Advisor Global Operations Team Insights & Resources About Us Our Story The Goodwin Way Opportunity, Inclusion, and Belonging Pro Bono Firm Leadership Locations News & Events Alumni Arman Oruc Partner Co-Chair, Antitrust + Competition Washington, DC +1 202 346 4440 Silicon Valley +1 650 752 3131 Arman Oruc Washington, DC +1 202 346 4440 View PDF VCard Email Share Arman Oruc is co-chair of Goodwin’s Antitrust and Competition practice. He specializes in antitrus … to Pfizer for $2.26 billion Past litigation matters include: Successful amnesty application with the DOJ for Japanese automobile light maker* Kintetsu Worldwide in numerous antitrust investigations and civil litigations* Co-counsel for Weyerhaeuser in the seminal monopsonization litigations* Lead counsel for Staples in antitrust litigations and government investigations related to product design and strategy issues surrounding private label ink cartridges compatible with HP-b
SM-04646 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 20 Jun 2026 SM-04646 Last update 20 Jun 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms LNG01, SM 04646 Target Wnt Action inhibitors Mechanism Wnt inhibitors Therapeutic Areas Respiratory Diseases Other Diseases Active Indication - Inactive Indication Idiopathic Pulmonary Fibrosis Originator Organization Biosplice Therapeutics, Inc. Active O … dministration (FDA) in support of an efficacy supplement to the Tyvaso new drug application (sNDA), which we expect to result in revised labeling reflecting the outcome of the INCREASE study. In August 2020, the FDA accepted the sNDA for review, which we expect will be complete in April 2021. Remunity Pump for Remodulin. We commenced launch activities for the Remunity Pump for Remodulin, including shipping training devices to specialty pharmacies and certain health care pract … icians and patients may experience. Trevyent. We submitted a 505(b)(1) new drug application (NDA) to the FDA for our Trevyent disposable treprostinil pump system in June 2019. In April 2020, the FDA issued a complete response letter (CRL) related to our NDA indicating that some of the deficiencies previously raised by the FDA had not yet been addressed to its satisfaction. We have one year from the date of the CRL to resubmit our NDA to the FDA, which is expected to trigger a … loped in collaboration with Medtronic, Inc. (Medtronic), the premarket approval application (PMA) for the ISR was approved by the FDA in December 2017. However, our ability to launch the product is subject to Medtronic satisfying various conditions to its PMA approval. Medtronic continues to work toward satisfying these conditions, but in December 2019, due to FDA communications, Medtronic informed us that these conditions will not be satisfied in 2020. As such we expect a de … 2020 to discuss the content needed to support a supplemental biologics license application (BLA). We are working with Children's Oncology Group to secure additional information ahead of a potential supplemental BLA. During the third quarter of 2020, we discontinued our efforts to investigate Unituxin's potential activity against adult cancers, a
OSR Holdings 10-K details pipeline and SPAC deal | OSRH Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stoc … to Acquire Synaptics to Enable the Next Generation of Inte... DLHC DLH Contract Award Opens New Growth Channels with U.S Navy ILLR Triller Group (Nasdaq: ILLR): The Reverse Split Is Not the Story ... RKLB NASA Selects Rocket Lab to Launch Sun, Earth Sciences Missions SHPH United Dogecoin Advances Data Centre and Power Infrastructure Str... TII Titan Mining Selected by the U.S. Army to Establish First-Ever Pu... ON onsemi to Acquire Synaptics to Enable the Next Generation of I … to Acquire Synaptics to Enable the Next Generation of Inte... DLHC DLH Contract Award Opens New Growth Channels with U.S Navy ILLR Triller Group (Nasdaq: ILLR): The Reverse Split Is Not the Story ... Previous Next --> Overview Financials News SEC Filings OSR Holdings (NASDAQ: OSRH) outlines cancer, ortho and medtech growth plans Filing Impact (Moderate) Filing Sentiment (Neutral) Form Type 10-K Rhea-AI Filing Summary English Italian Spanish German Korean French Arabic OSR Hol … eding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and &# … ce for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are in force for 20 years from the earliest nonprovisional filing date.
Acute Myeloid Leukemia - Drugs, Targets, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Acute Myeloid Leukemia Last update 08 May 2025 Basic Info Synonyms ACUTE MYELOBLASTIC LEUKEMIA, ACUTE MYELOGENOUS LEUKEMIA, AML + [258] Introduction Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Related 1,725 Drugs associated with Acute Myeloid Leukemia Revumenib Target menin Mechanism menin inhibitors Act … o drive progress across our programs.” Recent Highlights Submission of New Drug Application for ziftomenib to FDA – Kura and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced submission of the New Drug Application (NDA) for ziftomenib for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation to the U.S. Food and Drug Administration (FDA) on March 31, 2025 . From the time of submission, the FDA has a 6 … short-term investments as of March 31, 2025 will be sufficient to enable us to fund our current operating expenses into 2027 and, combined with anticipated collaboration funding under the Kyowa Agreement, should support our ziftomenib AML program through commercialization in the frontline combination setting. Forecasted Milestones Present data from the KOMET-001 Phase 1b/2 registration-directed trial in R/R NPM1-m AML at ASCO and EHA in the second quarter of 2025. Present pr … eet and the sufficiency of cash, cash equivalents and short-term investments to fund its current operating plan to 2027 and, combined with anticipated collaboration funding under the Kyowa Agreement, to support Kura’s ziftomenib AML program through commercialization in the 1L combination setting. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/
%PDF-1.6 %���� 1136 0 obj > endobj 1149 0 obj >/Filter/FlateDecode/ID[ ]/Index[1136 21]/Info 1135 0 R/Length 85/Prev 2777826/Root 1137 0 R/Size 1157/Type/XRef/W[1 3 1]>>stream h�bbd```b``s� � �ID2���� ��7X�D.� $'-�7R�$��3 qn ��A,#��i �8�� �_�# endstream endobj startxref 0 %%EOF 1156 0 obj >stream h��T�O[U��mw����^���^t�q�B����/�� ��@-e�Q Ka�x%�6[�����`�,�9 t�e&6�E�:_2]�`��e��7��{�R�oν�y~�����9����۠����Gr�R@ bL���,��2��`3J�E1� W�~F�b���F{�Sr�i��F�=��2���z�F�O��0 9y��f�r� k�ۛR6��3?�l��R6����Қ ̓Nlww���� �g��m0��� �Z���v��> {�J�is�3P�w�ﲟ��T4�8����� … 5b5344d-0b5a-4998-9ee7-b932fbc1e5bb uuid:5cb33600-4f3d-4b82-9763-b3ae3200d7d5 2 application/pdf Mizobe, Ami Adobe PDF Library 24.3.212 endstream endobj 254 0 obj >stream hޜS1N1 ����cljt����t�C'�B4�������J�n�3����$�,F���, ^��>�$�I�l+ɉ4�J��}%B%�I�R�D�]�p���n�m�}�>v�D�p��4����A� ������c�N���z >stream h�l�AK�0���)�v�VpeY(��h������͈Qۑ1A�W�"��}�y|o��.���lR|d�]����U3����i�9�� |u�r"!ϭ���+��6h/ Vn�p�B\����� �A��JG sd�A̹����� �/ ,�EyC�;�?mw����7� �4�����U���m�ɢl����آ
%PDF-1.7 %���� 266 0 obj > endobj 285 0 obj >/Encrypt 267 0 R/Filter/FlateDecode/ID[ ]/Index[266 35]/Info 265 0 R/Length 95/Prev 1027605/Root 268 0 R/Size 301/Type/XRef/W[1 2 1]>>stream h�bbd``b`��W�C+��J�ʀ+�\ $�S��3 !� HH�t�$��@�$�&���� �hpa`bd� 2���"�?���9 M endstream endobj startxref 0 %%EOF 300 0 obj >stream O� wƮ��X��bn�}�[s�hLV���S-��A�L ̜�G�r�:�@��:�� ����^;��xs��79���Ĝ8�A�[��o�?f=�g J�g5��a��j%� ���M�uoJ�h�i�!MC3�.a�0[g��Gܕ�"��[�Wk�'�A�no�P���m�\t8�@�š:��ɕeP���GmF� ��2�����:jl�T=Ӆ��b��p|"B�����3��#C�b�qF���*��ؘ�pv`��g��d��D �9�ż ;� endstream end
EUPRAXIA PHARMACEUTICALS INC. (Form: F-10, Received: 01/18/2024 16:04:42) Table of Contents As filed with the Securities and Exchange Commission on January 18, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EUPRAXIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Not applicable (Translation of Registrant’s name int … ow in future periods, it may need to allocate a portion of its cash reserves to fund such negative cash flow. The Company may also be required to raise additional funds through the issuance of equity or debt securities. There can be no assurance that the Company will be able to generate a positive cash flow from its operations, that additional capital or other types of financing will be available when needed or that these financings will be on terms favourable to the Company. … require the issuance of additional Common Shares and the Company is expected to grant additional stock options. Any Common Shares issuances from the Company’s treasury will result in immediate dilution to existing shareholders’ percentage interest in the Company. The Company has warrants, convertible debt, and shares of a subsidiary exchangeable for Common Shares outstanding, which in each case, if exercised, converted or exchanged, respectively, could cause dilutio … hich would require the issuance of additional Common Shares and the Company may grant additional share purchase warrants or stock options. Any share issuances from the Company’s treasury will result in immediate dilution to existing shareholders’ percentage interest in the Company. Our Common Shares may have limited liquidity. Shareholders of the Company may be unable to sell significant quantities of Common Shares into the public trading markets without a significa … ecified in the applicable prospectus supplement, the Company does not intend to apply for listing of the preferred shares, debt securities, warrants, subscription receipts or units on any securities exchanges. If the preferred shares, debt securities, warrants, subscription receipts or units are traded after their initial issuance, they may trade
Instagram Instagram Log In Sign Up Close Never miss a post from creaky_joints Sign up for Instagram to stay in the loop. Sign up Log in creaky_joints Verified • Follow More options creaky_joints Verified Edited • 16w For people living with osteoarthritis, headlines about new treatments often raise more questions than answers. In the latest episode of #TheHealthAdvocates , we speak with Erich Horsley, CEO of Biosplice Therapeutics, and Dr. Yusuf Yazici, Chief Medical Officer, about what it really means when a company submits a New Drug Application (NDA) to the FDA. The conversation breaks down:
424B4 1 absci424.htm 424B4 Document Filed Pursuant to Rule 424(b)(4) Registration No: 333-257553 Prospectus 12,500,000 shares Common stock This is an initial public offering of shares of common stock by Absci Corporation. We are offering 12,500,000 shares of our common stock to be sold in the offering. The initial public offering price is $16.00  per share. Prior to this offering, there has been no public market for our common stock. Our common stock has been approved for listing on the Nasdaq Global Market (Nasdaq) under the symbol “ABSI.” We are an “emerging growth … e samples or bulk RNA sequencing data of interest to our partners, we expect to apply our newly acquired computational antibody and target discovery technology to reconstruct sequences of human monoclonal antibodies that are prevalent in the tissue. With our SoluPro expression system and adapted versions of our ACE Assay we believe we can rapidly de-orphan the antibodies, using them as probes to identify their corresponding antigens. Not only are the antigens, whether known o … ven if this offering is successful, we will need to raise additional capital to fund our operations and improve our platform. If we are unable to raise additional capital on terms acceptable to us or at all, we may need not be able to compete successfully, which would harm our business, operations and financial condition. • Our historical revenue is primarily related to technology development services, and our revenue for any historical period may not be indicative of r … ercialization efforts. • We are substantially dependent on the successful application of our Integrated Drug Creation Platform to Discovery and Cell Line Development partnerships, and we have only recently begun to enter into Discovery partnerships. • If we cannot maintain our current relationships with partners, fail to expand our relationships with our current partners, or if we fail to enter into new relationships, our future operating results would be adversel … f our common stock reserved for future issuance under our 2020 Stock Option and Grant Plan (2020 Plan) as of March 31, 2021; •  8,133,750 shares of our common stock reserved for future issuance under our 2021 Stock Option and Incentive Plan (2021 Plan) which became available for issuance upon the effectiveness of the registration s
[2023 JP Morgan Healthcare Conference] ABL Bio aims to license out 2 bispecific antibodies after Sanofi deal 주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기 잠깐! 현재 Internet Explorer 8이하 버전을 이용중이십니다. 최신 브라우저(Browser) 사용을 권장드립니다! ie 인터넷 익스플로러 11 다운로드 chrome 구글 크롬 다운로드 firefox 모질라 파이어폭스 다운로드 상단영역 UPDATE : 2026-06-25 17:01 (Thurs) Home Log in Join 전체메뉴 기사검색 검색 본문영역 이전 기사보기 다음 기사보기 [2023 JP Morgan Healthcare Conference] ABL Bio aims to license out 2 bispecific antibodies after Sanofi deal 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 스크롤 이동 상태바 현재위치 Home Special [2023 JP Morgan Healthcare Conferen … forming Biosplice drug in animal tests Comments Log In 작성자 비밀번호 댓글 내용입력 0 / 400 Submit 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More Delete comments Deleted comments cannot be recovered. Do you still want to delete it? Password Delete 닫기 Modify the comments You can modify comments only within 1 minute after writing. Text / 400 Password Modify 닫기 My comme
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
%PDF-1.7 %���� 1 0 obj >/Metadata 1070 0 R/ViewerPreferences 1071 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 4032 2688] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}[s�F��#� �1h��P7��L�HɖmqF�T�w�܇f${���H� �����?�N��59M/|A_��I�}�9�Y^&�Ƅ %3x ~�Y!�*���O��C]$�� ��!>ߑ +�R&p��*x��*��C�v �"�K��:�/��%��T�|��#F�H� 9cY��s$�Q� C��ǯ���{x����I>���Wo>؉Ɵ�[ � �����^�#�ng��t �,��}2R�汆O���d6]$�G�ъ8h%�2` � 2 Qe\9Q\��E�, �7H�z�Y��(�S�)/A��!�ERD-��Hҋw��Q>�I#ɤ�I ���l� �b%4p@_ի)rZ��`�@ ��
%PDF-1.7 %���� 1 0 obj >/Lang(en-US)/Metadata 127 0 R >> endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Font >>>/MediaBox[ 0 0 720 405]/Type/Page/Parent 2 0 R /Contents 4 0 R /Tabs/S/Group >>> endobj 4 0 obj >stream x��\�S�H�N��>�WAh���t������r�K���J ��6^Y�������Л����y�����cNϋru��J�������(�� ��2&D�%Q��Px����y��ӟ��n|ļ�jt �6F������G�%,{�ل&�0�2���0�� �����I�l�|��w �]�{f+���������Å��y�.�����V{� a�_���~6�4z���o=X�\.�]��������bj���uN g�I���'�ס!���a��G����o��O ��v�L]���� ����U�" � �s��P> ��EG�o~�^�T�&v��ޛ�L��5��&�H���O�� ����Ӛ4� �9�� :|�����X��9]�2
Publications | Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Biosplice Therapeutics has widely presented its science and data. Please refer to the website of our affiliate TenaRx, Inc. for publications related to our programs outside of lorecivivint. Please find below publications related to lorecivivint. Filter Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo - Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07) America … Osteoarthritis American College of Rheumatology (ACR) | November 06 - 11, 2015 Award Winning Privacy Policy Terms of Use Contact Us © Biosplice Therapeutics, Inc. All rights reserved.
Osteoarthritis | Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Osteoarthritis Unmet Need Lorecivivint (SM04690) Publications Corporate Memberships and Collaborations Request Info Osteoarthritis (OA), the most common form of arthritis, is a serious chronic disease that affects an estimated 51.9 million U.S. adults 1 and 527.8 million adults globally. 2 Osteoarthritis is the most prevalent joint disease and a leading source of chronic pain and disability in the United States. 3,4 … pain and function as well as structural benefit. Biosplice submitted a new drug application (“NDA”) to the US Food and Drug Administration in late 2025. In various well-controlled studies, lorecivivint has demonstrated improvements versus placebo in pain, function and medial joint spade width (“mJSW”) as measured by x-ray (a measure of disease progression). Read More… Mechanism of Action Since its discovery in the early 1980s the Wnt pathway has increasingly been recognized a … Osteoarthritis American College of Rheumatology (ACR) | November 06 - 11, 2015 Award Winning Corporate Memberships and Collaborations ORBIT Registry (Brigham and Women’s Hospital) Biosplice Therapeutics is sponsoring the Osteoarthritis Registry of Biomarker and Imaging Trajectories (ORBIT). The data from this study will enhance our understanding of the natural history of knee osteoarthritis. This registry was developed in collaboration with investigators at Brigham and Women
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Dave Johnson Joins Biosplice Therapeutics Board of Directors | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real
Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Targeting the root cause of disease; not settling for symptom relief. TECHNOLOGY Stem cells can divide and multiply to produce further stem cells and/or differentiate into specialized cells that form the various tissues and organs in our bodies. In contrast to embryonic stem cells, which differentiate into all the specialized cells in a developing embryo, adult stem cells repair and replenish the various tissues in adult organisms. T
Publications | Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Biosplice Therapeutics has widely presented its science and data. Please refer to the website of our affiliate TenaRx, Inc. for publications related to our programs outside of lorecivivint. Please find below publications related to lorecivivint. Filter Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo - Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07) America … Osteoarthritis American College of Rheumatology (ACR) | November 06 - 11, 2015 Award Winning Privacy Policy Terms of Use Contact Us © Biosplice Therapeutics, Inc. All rights reserved.
Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Over 50 million US patients suffer from osteoarthritis, with no drugs available to arrest the disease. Learn more about our investigational drug candidate, lorecivivint. Learn More Privacy Policy Terms of Use Contact Us © Biosplice Therapeutics, Inc. All rights reserved.
Biosplice Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Biosplice Therapeutics, Inc. Holding Company | 2008 | California, United States | 50-100 | www.samumed.com Holding Company | 2008 | California, United States | 50-100 | www.samumed.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Biosplice Therapeutics is a company that specializes in medical research and development for ti … Jan 2026 · www.biospace.com Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and medial joint space width when compared with placebo, along with very good safety SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE … ter over a decade of clinical trials, we are pleased to be the first company to submit a data package in the US for a potentially disease-modifying drug in knee OA for approval. As many knee OA patients are aware, the patient journey for someone diagnosed with OA is currently painful and disheartening. We are excited about the prospects of materially improving the OA patient’s journey with a new treatment that is both safe and effective and has the potential to delay further … ote chondrocyte formation and the protection of hyaline cartilage. Any new drug application in OA must be supported by a good safety profile. Throughout the decade-long clinical development program, LOR’s safety pro been consistent with and similar to that of placebo. LOR’s safety is enhanced by the fact that, when injected into the knee joint, the drug has no detectible systemic exposure throughout the body. Professor Tim McAlindon, from UMass Chan School of Medicine, who ha … statements regarding the review and potential approval of Biosplice’s New Drug Application for lorecivivint and the therapeutic potential of lorecivivint. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and un
Biosplice Archives | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real Estate Healthcare Non-Profit Education pro … Rohrbaugh Named Co-President of JPMorgan Chase June 25, 2026 Robinhood Ventures Fund I Invests $25M in Canva June 25, 2026 McCormick Projects 2026 Margin Expansion, Reaffirms EPS Growth From Pending Unilever Foods Deal June 25, 2026 Cyphlens Adds Former National Security Official Jon Finer, Launches CypherFile Security Platform June 25, 2026 Freedom Bank Appoints Sheila K. Stabile to Board of Directors All Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Da
Samil Pharm-linked osteoarthritis drug advances toward US FDA approval 주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기 잠깐! 현재 Internet Explorer 8이하 버전을 이용중이십니다. 최신 브라우저(Browser) 사용을 권장드립니다! ie 인터넷 익스플로러 11 다운로드 chrome 구글 크롬 다운로드 firefox 모질라 파이어폭스 다운로드 상단영역 UPDATE : 2026-06-25 17:01 (Thurs) Home Log in Join 전체메뉴 기사검색 검색 본문영역 이전 기사보기 다음 기사보기 Samil Pharm-linked osteoarthritis drug advances toward US FDA approval 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 스크롤 이동 상태바 현재위치 Home Pharma Samil Pharm-linked osteoarthritis drug advances toward US FDA approval 기자명 Park Gi-taek Published 2026.01.07 15: … said Wednesday that U.S.-based Biosplice Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lorecivivint, a treatment for knee osteoarthritis. Samil Pharmaceutical holds exclusive domestic distribution rights to the drug in Korea. Samil Pharmaceutical’s headquarters in Bangbae-dong, southern Seoul Biosplice Therapeutics is a San Diego-based biotech company developing small-molecule therapies that inhibit CLK/DYRK … forming Biosplice drug in animal tests Comments Log In 작성자 비밀번호 댓글 내용입력 0 / 400 Submit 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More Delete comments Deleted comments cannot be recovered. Do you still want to delete it? Password Delete 닫기 Modify the comments You can modify comments only within 1 minute after writing. Text / 400 Password Modify 닫기 My comme
Biosplice (was Samumed) – SM04690 Osteoarthritis of the shoulder Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join th
Biosplice (was Samumed) – Cirtuvivint (SM08502) additional solid tumors Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes
Biosplice (was Samumed) – Cirtuvivint (SM08502) mCRPC,CRC,NSCLC Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Osman Kibar - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Print/export Download as PDF Printable version In other projects Wikidata item Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Early life and education 2 Career 3 Personal life 4 References Toggle the table of contents Osman Kibar 2 languages Kiswahili Tür … ing his education, Kibar moved to New York City , where he worked for the hedge fund sponsor Pequot Capital . [ 10 ] He subsequently moved back to San Diego and in August 2011 founded a biotechnology company named Wintherix with an investment of $3.5 million from his friend Cevdet Samikoğlu. [ 6 ] He later renamed the company Samumed, and subsequently Biosplice . [ 4 ] Its investors include Ali Sabancı and Ergun Özen. The company researches cures … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Osman Kibar 2 languages
Biosplice Therapeutics Inc. - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> Biosplice Therapeutics Inc. Modulating alternative splicing factors . Formerly Samumed. Website Profile prev next Website Bookmark Share prev next General Headquarters San Diego, California 92121, United States Founders & Team Osman Kibar, Cevdet Samikoglu, Yusuf Yazici, Arman Oruc, Neil Bair, Blake Mobley, Erich Horsley, Philippe Marchand Y
Biosplice Announces First Patient Dosed in Phase 2 Trial of --> Accessibility: Skip TopNav Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes May 01, 2025 06:00 ET | Source: Biosplice Therapeutics, Inc. Biosplice Therapeutics, Inc. SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC
Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Management Erich Horsley Chief Executive Officer Mr. Horsley has two decades of experience building businesses as a private equity investor and entrepreneur. Most recently, he was a Partner and a founding member of Intervale Capital, a Boston-based private equity firm with multiple funds under management. Previously, Mr. Horsley worked as a Principal at Watermill Group, a generalist private equity firm, and as an investment banker at … ven numerous national and international presentations. Dr. Yazici completed his Fellowship in Rheumatology at the Hospital for Special Surgery of Weill Medical College of Cornell University in New York and Residency in Internal Medicine at Creighton University in Nebraska. Dr. Yazici received his medical degree from Istanbul University. Phil Wilson Chief Financial Officer Mr. Wilson serves as Chief Financial Officer at Biosplice Therapeutics. He brings over 15 years of financ
Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account January 06, 2026 06:30 ET | Source: Biosplice Therapeutics, Inc. Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis Biosplice announces submission of new drug application to US FDA for treatment of knee osteoarthritis December 22, 2025 06:00 ET | Source: Biosplice Therapeutics, Inc. Biosplice Therapeutics Announces First P … Therapeutics, Inc. Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense. November 13, 2023 06:00 ET | Source: Biosplice Therapeutics, Inc. Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Tri
Biosplice Therapeutics Inc. - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Biosplice, Novo Nordisk Partner to Develop Drug Candidates for Treatment of Diabetes | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscrib … and potent DYRK inhibitors. Under the terms of the agreement, Novo Nordisk will fund further preclinical development, with an exclusive option to license Biosplice’s relevant intellectual property primarily focused on cardiometabolic disorders. Specific financial terms were not disclosed. “We are extremely pleased to combine our unique DYRK inhibition expertise with Novo Nordisk’s leadership in diabetes treatments,” commented Erich Horsley, CFO and CBO of Biosplice. “For over
11th Annual Outsourcing in Clinical Trials Southern California 2023 - Arena International --> Home About Us Events Contact Us Why attend? Agenda Speakers Plan Your Visit Event Gallery Sponsors Contact Us Download Agenda Registration Closed 11th Annual Outsourcing in Clinical Trials Southern California 2023 Arena International are delighted to announce the Outsourcing in Clinical Trials Southern California Event will be returning to California’s La Jolla on September 26th & 27th 2023! Start 26 Sep End 27 Sep Hyatt Regency La Jolla at Aventine, San Diego, USA Regi … werment allows for creative and rapid customized solutions Customized solutions apply to both technology and contracting Speakers Dorothy Blythe Principal Clinical Data Manager, TFS Health Science 12:45 PM Lunch and Networking JOIN ONE OF OUR NETWORKING TABLES Eat lunch with a like-minded group of industry colleagues by joining one of our lunchtime discussion groups on the topics below: TABLE 1: Patient enrollment, what are we doing to improve uptake in new trials. TABLE 2: F … nt, Calidi Biotherapeutics 2:30 PM Afternoon Refreshments and Networking; Apple Prize Draw 3 PM Speaker Hosted Roundtables Speaker Hosted Roundtables Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network … ery in the pharma industry. She has a PharmD and a PhD and did her postdoctoral fellowship at the University of Pennsylvania in Philadelphia. Tanja Obradovic Dr. Obradovic has over 25 years of experience in clinical pharmaceutical development in Oncology. After holding academic appointment of Research Assistant Professor at Temple University of Pharmacology leading Immunooncology laboratory she joined pharmaceutical industry. She was holding senior positions at Merck within O … ies enabling investigators and sponsors to simply record, review, anonymise and submit assessments to regulatory bodies. Company Website To learn more, please visit our website - https://www.chillipharm.com/ Back Company Information ClinChoice is a leading global full & functional service CRO, renowned for its exceptional product development
The Health Advocates - Podcast - Apple Podcasts Search Home New Top Charts Search The Health Advocates Global Healthy Living Foundation 4.8 (46) Health & Fitness Updated Weekly A podcast that breaks down major health news of the week to help you make sense of it all. Our goal is to help you understand what’s happening in the healthcare world to help you make informed decisions to live your best life. Latest Episode Follow Episodes 5h ago S9, Ep 13- What Patients Need to Know: Research, Innovation, and the Patient Voice At EULAR 2026 What happens at one of the world's largest rheumatology c … and public trust. From the FDA’s decision not to review a new mRNA flu vaccine application to reports of delayed vaccine safety studies and shifting federal recommendations, the episode connects a series of recent developments that together point to a broader transformation inside federal health agencies. The conversation examines why some officials argue these changes are restoring scientific rigor, while many scientists and public health advocates worry they are creating c … w things down to explain what it really means when a company submits a New Drug Application, or NDA, to the U.S. Food and Drug Administration. Steven Newmark is joined by Erich Horsley and Dr. Yusuf Yazici from Biosplice Therapeutics to walk through this important regulatory milestone and why it matters for patients. Together, they break down what an NDA is, what happens during FDA review, and what patients should and should not expect while a therapy is under evaluation. The
BioSplice Therapeutics - SymBiosis Capital Management Skip to Main Content Home Team 17 Investments 26 News 367 Careers 2 Home Team 17 Investments 26 News 367 Careers 2 Back to Investments --> --> --> --> --> --> --> --> BioSplice Therapeutics Financing Round Series B Biosplice is pioneering first-in-class, small molecule therapeutics based on CLK/DYRK kinase modulation. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative pre-mRNA splicing, as well as other biological mech … ive conditions. Related News Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer Biosplice Announces Collaboration with Novo Nordisk in Diabetes Biosplice Presents Successful Structure and Pain Results from Completed Phase 3
Search page Go to search page Cancel About ICA Gruppen About ICA Gruppen › Our business Our values Strategy Community engagement Organization Corporate governance Our business › Our companies Business model Markets Our brands Our history Our companies › ICA Sweden Apotek Hjärtat ICA Bank ICA Real Estate Corporate governance › Board of Directors Executive Management Reports Annual General Meeting Policies and guidelines Auditors Sustainability Sustainability › Sustainability governance Our sustainability work Sponsorship Question and answer Sustainability governance › Materiality analysis
Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Board of Directors Osman Kibar, PhD Founder and Executive Chairman, Biosplice Therapeutics Dr. Kibar is an entrepreneur and an inventor, with numerous successful start-ups under his belt. He was the Scientific Founder of Genoptix (an oncology diagnostics company), which went public in 2007 (NASDAQ: GXDX) and was later acquired by Novartis in 2011. Dr. Kibar was also a Co-Founder of E-Tenna, whose assets relating to wireless antennas … eived his Doctor of Philosophy from Cambridge University on the Shell/Cambridge Scholarship. He received his B.Sc. Degree in Engineering from the University of Glasgow, where he also won all the academic awards available for the examinations, including an award for being the top student for his course, as well as the most distinguished graduate award. Board Observers Chidozie Ugwumba Managing Partner, SymBiosis Chidozie Ugwumba serves as Managing Partner of SymBiosis, a ventu … in Philosophy from Washington & Lee University. He is a member of the Kauffman Fellowship (Class 23). Ahmed Khizer Khan Chief Executive Officer - Daman Investments & Board Advisor Mr. Ahmed Khizer Khan is the CEO of Daman Investments, a pioneer firm in the UAE's financial services industry. Mr. Khan is a globally recognized business leader, banker and change agent with over three decades of global leadership experience. After an Honors degree in Economics from Bucknell, and
Biosplice Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Biosplice Therapeutics, Inc. Holding Company | 2008 | California, United States | 50-100 | www.samumed.com Holding Company | 2008 | California, United States | 50-100 | www.samumed.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Biosplice Therapeutics is a company that specializes in medical research and development for ti … Jan 2026 · www.biospace.com Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and medial joint space width when compared with placebo, along with very good safety SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE … ter over a decade of clinical trials, we are pleased to be the first company to submit a data package in the US for a potentially disease-modifying drug in knee OA for approval. As many knee OA patients are aware, the patient journey for someone diagnosed with OA is currently painful and disheartening. We are excited about the prospects of materially improving the OA patient’s journey with a new treatment that is both safe and effective and has the potential to delay further … ote chondrocyte formation and the protection of hyaline cartilage. Any new drug application in OA must be supported by a good safety profile. Throughout the decade-long clinical development program, LOR’s safety pro been consistent with and similar to that of placebo. LOR’s safety is enhanced by the fact that, when injected into the knee joint, the drug has no detectible systemic exposure throughout the body. Professor Tim McAlindon, from UMass Chan School of Medicine, who ha … statements regarding the review and potential approval of Biosplice’s New Drug Application for lorecivivint and the therapeutic potential of lorecivivint. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and un
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
Invest In Biosplice Therapeutics Stock | Buy Pre-IPO Shares | EquityZen We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences Sign Up Today and Learn More About Biosplice Therapeutics Stock Invest in or calculate the value of your shares in Biosplice Therapeutics or other pre-IPO companies through EquityZen's platform. Get Started View More Companies Biosplice Therapeutics Stock (BITH) Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Invest Now Sell Shares About Biosplice Therapeutics St … in the know about the latest news on Biosplice Therapeutics Biosplice files FDA application for knee osteoarthritis drug longevity • Jan 16, 2026 Biosplice Therapeutics submits NDA to FDA for lorecivivint to treat knee osteoarthritis longevity • Jan 08, 2026 Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis globenewswire • Jan 06, 2026 Biosplice Therapeutics doses first patient in Phase 1 ovaria … their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investmen … on FINRA’s BrokerCheck . EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen. EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They
EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE PARTNERSHIP FOR METASTATIC CANCER TRIALS Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos A … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Biosplice Doses First Patient in AML/MDS Clinical Trial Moe Alsumidaie Chief Editor Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation. Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Cell and Gene Therapy Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Innovation Clinical Trial Operations
%PDF-1.5 %���� 1 0 obj >/AcroForm >>> endobj 3 0 obj >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]>>/MediaBox[ 0 0 1224 792]/Contents 4 0 R /Group >/Tabs/S/StructParents 0>> endobj 4 0 obj >stream x��}[s DZ�"� �3'���n�0B�䳲M�kѫؐ�0 �E�r����̬��L�@Bg���H�_gUV�/g_ u�鐟��K��˲�C�o��w�@ToD���r��d�.�wֶ�� j��Z\����� Y)L���g��J�t=s��t��+����%p�+��K�+��C�����.e �-���go�[��d�-�$ً��7'��4X�{�_.{Cb�v�gI6����Q������J���]w�U|���\l��[����0�O�����%�l-�e� �~0;n�aK�ҳ �f �O\�%� ����-�8/lt��b����L ^ja�?�%���⇧�Ƚ%�� [0�>�a3�u��^ ��.y��̡�3��=�D�\ɢ�DRY��lr�#�u{�o�B��Lũ��wٓ|�����֭�`��f���D�G4H/6u} … :���Ƭ�����M�i��r�b4�u��.3R;n�8Ŵ��c Y�r%Z]�t�r����F��Y ��>}:���~��իWO �3�RFPÒ%K� �03eҡs ��RCC4�@b�cƌAK,,�����6���H��k"���!�aaatG$� 5�T�T����������W'��8ㅿ�M RKݺuC �+�...V��ȑ#�eȬ�~�b4%L@�h�R�`!���ƿR ={�lӦ�brbg �X�H��3�9�$X�3� ���O�W��b�:��T"8�j�[H-~R�t��H� ��K|p�ҵk� =zX&�H$�D"�H$�>��K�.b�5�J�+���?��X�����*�m۶=u�T~~~���՛�,E{���:��-k���6l`�ݠAV� :t�3g��2�h4/��2�Y�:�ԩ��c�$�q�֭K=ݻw�K,�֭[G�5j�@��Ç;;;�� ��������}���Ν;SI�6mD8.
%PDF-1.7 %���� 1 0 obj >/Lang(en-US)/Metadata 107 0 R >> endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Font >>>/MediaBox[ 0 0 612 792]/Contents 4 0 R /Parent 2 0 R /Type/Page/Tabs/S/Group >>> endobj 4 0 obj >stream x��][s�F�~w�� �R�) �`p�J�J�d�6�h-ũ�x `��@�R���Ow� ��"m3��m������7�W����,fk�� _ ���쪜{���hn������|uV,�e�����ۯk�� e1/ۃ������� ����K��4��|����/_��x�������˗/�x�1�~����ិ穷X���}����/_�:���.���� ��_/_ l���(q9��QkԽ�O5�D��5l�%1��1" �Q&����I�q� �{� �s0��� B�}� |����ħ� ����?�b�L��� ��[���D�Y�����bUΧR��f�Q�_�0� �F��J.k#Α��cȚ3����l A�:���
Privacy Policy | Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Your Privacy BIOSPLICE PRIVACY POLICY Biosplice Therapeutics, Inc. (“Biosplice," “we," “our," or “us") respects your individual privacy. This Privacy Policy puts you in control of how your personal information is used in connection with any of our web sites, including biosplice.com and any other sites we sponsor or control that direct you to this policy (collectively, the “Site"). This Privacy Policy describes how we … hnologies.") If you reach out to us via the "Contact us" prompt, submit a comment, complete a visitor survey, or other similar interaction with us through the Site, we may collect the following types of information from you: your name, email, address, phone number(s), information relating to your health or medical condition and/or other information that may be requested and/or provided. You can freely visit many portions of our Site. However, some of our servic … or maintenance of our Site. The privacy policies of such third parties may also apply. We may also disclose your personal information and other information to third parties if disclosure is required to comply with applicable laws or regulations or where Biosplice may be required to share your information with third parties such as with health authorities to report possible adverse product experiences, during inspections or audits, or as ordered or directed by courts or other … olicy are compliant with laws outside of the United States including those that apply to the collection, security, use, and disclosure of personal information. Indeed, the United States may not offer a level of privacy protection as great as that offered in other jurisdictions. 13. REVISIONS TO THIS POLICY We may revise the Privacy Policy from time-to-time in our sole discretion. Please visit this Site and review our Privacy Policy periodically for changes. By continuing to a
%PDF-1.7 %���� 1 0 obj >/Metadata 101 0 R/ViewerPreferences 102 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\Yo�H�~���� i`�,��08���3���I}�y�mZ�5�l����S+�8vW���)�X���|g)�� ��mq}���NϏ������~;����y��i_�~(6ծ8V������o�\7�a���]���}����� ��M��;�o���'o��ͻ�oߜ^2 |�}��A����Y�'�6L}x��6?}J�M �y���_?�}��̛�����o�����}� �hh�r� >��l�i�Hf�O �_D���h�~�>�Gts��5� �S�M���`/\���A�]�ȏ��KRxF�n�gU3Of� ס�����Ko �������v-�+�q�]��������vG���ǻ
%PDF-1.7 %���� 1 0 obj >/Metadata 1558 0 R/ViewerPreferences 1559 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 720 405] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Vmo�H������,^�SE�xI��pm�wթ���^���)���Y���#""�{wv�y��l�[�j"�z�>|o6L0�� �6�� ��B�4_�A�l�o�.L͆����6]�yO�5�� �ư��$u�&Lޱ��: ������� �Yl8 �#��[(�. �6Cn6+g � �ۃ�G�`��6�)�{TeNޯ��Υ�eco��WE�\�>Y��������Q���`�|�7�����نx7^I�;~��}6��O��t�� �ן�"�� �RP%q}�� w^N� �-���A�z4##��z?O)V�L7����j� �X'�pF�Jw�s� �;���7 �5p:��rz-���T
Osteoarthritis | Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Osteoarthritis Unmet Need Lorecivivint (SM04690) Publications Corporate Memberships and Collaborations Request Info Osteoarthritis (OA), the most common form of arthritis, is a serious chronic disease that affects an estimated 51.9 million U.S. adults 1 and 527.8 million adults globally. 2 Osteoarthritis is the most prevalent joint disease and a leading source of chronic pain and disability in the United States. 3,4 … pain and function as well as structural benefit. Biosplice submitted a new drug application (“NDA”) to the US Food and Drug Administration in late 2025. In various well-controlled studies, lorecivivint has demonstrated improvements versus placebo in pain, function and medial joint spade width (“mJSW”) as measured by x-ray (a measure of disease progression). Read More… Mechanism of Action Since its discovery in the early 1980s the Wnt pathway has increasingly been recognized a … Osteoarthritis American College of Rheumatology (ACR) | November 06 - 11, 2015 Award Winning Corporate Memberships and Collaborations ORBIT Registry (Brigham and Women’s Hospital) Biosplice Therapeutics is sponsoring the Osteoarthritis Registry of Biomarker and Imaging Trajectories (ORBIT). The data from this study will enhance our understanding of the natural history of knee osteoarthritis. This registry was developed in collaboration with investigators at Brigham and Women
Terms of Use | Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Terms of Use These are the terms of use ("Terms of Use" or "Agreement") applicable to our web sites, including biosplice.com and any other sites we sponsor or control that direct you to these Terms of Use (collectively, the "Site"). The Agreement is a legally binding contract between Biosplice Therapeutics, Inc. ("Biosplice," "we", "our," or "us’) and anyone who accesses or uses the Site ("you" or "your"). The Terms of … laws; (ii) the current Terms of Use; and (iii) any additional terms that might apply to a specific program accessible via, related to, or associated with the Site (collectively, "Program Terms") which, together, constitute an agreement between you and us. Your continued access or use of the Site following any changes to this agreement constitutes your acceptance of those changes. IF YOU DO NOT AGREE TO ALL OF THE TERMS AND CONDITIONS OF THE AGREEMENT WITHOUT MODIFICATION, TH … for no reason. You agree (and represent and warrant) that any User Content you submit (i) will not be unlawful or infringe on the rights of others; and (ii) will accurately express your views, beliefs and opinions. You also agree to be solely responsible for any damages resulting from any User Content you submit. All User Content submitted to us will be treated as non-proprietary and non-confidential. By submitting User Content to us, you automatically grant us the royalty-f … POSSIBILITY OF OR COULD HAVE FORESEEN THE EXCLUDED DAMAGES. THE FOREGOING SHALL APPLY REGARDLESS OF: (I) ANY NEGLIGENCE OR GROSS NEGLIGENCE OF BIOSPLICE; OR (II) ANY FAILURE OF AN ESSENTIAL PURPOSE; OR (III) WHETHER SUCH LIABILITY SOUNDS IN NEGLIGENCE, STRICT LIABILITY, CONTRACT, TORT OR ANY OTHER THEORY OF LEGAL LIABILITY. IN THOSE JURISDICTIONS THAT DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR THE EXCLUDED DAMAGES, BIOSPLICE’S LIABILITY SHALL BE LIMITED TO THE … disclaimers, exclusions, and limitations set forth in these Terms of Use do not apply; however, all other terms and conditions shall apply and remain in full force and effect. LINKS TO (AND COMMUNICATIONS WITH) THIRD PARTY SITES The Site may include links to other web sites (and/or web pages) and/or applications that are not maintained by us. We
Biosplice Therapeutics Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Biosplice Therapeutics Teams Biosplice Therapeutics Save Saved HQ San Diego 73 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Biotech Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology li
%PDF-1.7 %���� 1 0 obj >/Lang(en-US)/Metadata 105 0 R >> endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Font >>>/MediaBox[ 0 0 612 792]/Contents 4 0 R /Parent 2 0 R /Type/Page/Tabs/S/Group >>> endobj 4 0 obj >stream x��\[o�8�~����}�>pˢ$�|�lN2������>�m��u�Wj{���/���%�i/�dں��b�� y|�b��;>���}y��z|�l�q|��-���jS�fs|�p��[/�۲=9��.ν�}����� �D�?�C�-߾��_��훳�o��3O �//�; �Ū̽��My�?�{������ .������OC?c/ B�g� � s>���/���_,���f_������x�7/剥+,N}f�� �G�`r"�� � �� l@ 2�{�;z� �&$��T�X�J 2�� ����pF$�#� ��r �,7��a!�}�7��fW#���ڀwѬ� �� H'�\K \��ű e6*0�f �EV�s�3�9�
Biosplice | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Biosplice Website: Biosplice Business Area(s) RNA Protein Kinase Description Biosplice Therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the CLK/DYRK family kinases. These kinases govern the selecti
Biosplice Biosplice Toggle navigation About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Subscribe to Biosplice Therapeutics Updates Sign up below to receive updates on Biosplice’s therapeutic programs, clinical trials, publications, and company activity. First Name * Last Name * Company/Institution * Country * Email Address * Enter the Security Code * ( * ) Required fields. Submit For media inquiries, please contact Erich Horsley at: [email protected] 2026 Date Title Jan 06 Biosplice Announces the Submission of its Ne … e.com 2026 Date Title Jan 06 Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis 2024 Date Title Apr 18 Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results 2023 Date Title Nov 13 Bios … e’s Republic of China Sep 15 FierceBiotech: Haisco to Pay $140M to Get the Ball rolling on Biosplice's Phase 3 Osteoarthritis Drug in China Jul 22 Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients Apr 26 Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis Apr 22 Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea Apr
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tren … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Samumed And United Therapeutics Announce North American License Agreement For Samumed’s IPF Drug Candidate September 17, 2018 | 4 min read Twitter LinkedIn Facebook Email Print Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North … ment, United Therapeutics' subsidiary, Lung Biotechnology PBC, will conduct and fund all further development, regulatory and commercialization activities in the U.S. and Canada. Samumed retains development and commercialization rights for all markets outside of North America. "I've been impressed with Samumed's exhaustive work on the pleiotropic Wnt pathway from the time I met Dr. Kibar at this year's Cura Foundation conference on regenerative medicine, held at the Vatican," … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting September 29, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and... - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIB … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and... April 18, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Biosplice Thera … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea April 22, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China September 15, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc. (“Biosplice”), and Haisc … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors April 20, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alte … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Dea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis January 6, 2026 | 7 min read Twitter LinkedIn Facebook Email Print LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, … ter over a decade of clinical trials, we are pleased to be the first company to submit a data package in the US for a potentially disease-modifying drug in knee OA for approval. As many knee OA patients are aware, the patient journey for someone diagnosed with OA is currently painful and disheartening. We are excited about the prospects of materially improving the OA patient’s journey with a new treatment that is both safe and effective and has the potential to delay further … ote chondrocyte formation and the protection of hyaline cartilage. Any new drug application in OA must be supported by a good safety profile. Throughout the decade-long clinical development program, LOR’s safety profile has been consistent with and similar to that of placebo. LOR’s safety is enhanced by the fact that, when injected into the knee joint, the drug has no detectible systemic exposure throughout the body. Professor Tim McAlindon, from UMass Chan School of Medicine … statements regarding the review and potential approval of Biosplice’s New Drug Application for lorecivivint and the therapeutic potential of lorecivivint. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and un
Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform April 15, 2021 | 2 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-m … omprise Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management and others, and also includes existing investor support. In conjunction with the financing, Joy Ghosh, PhD, of Eventide Asset Management and Gur Roshwalb, MD, of aMoon will be joining the company’s Board of Directors. “We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice,” said Cevdet Samikoglu, Chief Executive Officer of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Announces Collaboration with Novo Nordisk in Diabetes - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press R … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Biosplice Announces Collaboration with Novo Nordisk in Diabetes June 13, 2024 | 4 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK k … and potent DYRK inhibitors. Under the terms of the agreement, Novo Nordisk will fund further preclinical development, with an exclusive option to license Biosplice’s relevant intellectual property primarily focused on cardiometabolic disorders. Specific financial terms were not disclosed, but would include upfront and milestone payments plus royalties for the exclusive license. “We are extremely pleased to combine our unique DYRK inhibition expertise with Novo Nordisk’s leade … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program March 8, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc. announced that its collaboration with The Roskamp … jury and Psychological Health Research Program (TBIPHRP) Translational Research Award” will fund preclinical development of Biosplice’s DYRK inhibitors in traumatic brain injury (TBI) models SAN DIEGO, March 08, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”) announced today that its collaboration with The Roskamp Institute (“Roskamp”), aimed at developing novel therapies for TBI using Biosplice’s promising small molecule DYRK (dual-specificity tyrosine ph … edical Research Programs (CDMRP). As part of the collaboration, the DoD TBIPHRP Award will fund Roskamp to undertake preclinical development in their well characterized TBI models using Biosplice’s DYRK inhibitors. This translational work could lead to future clinical trials for TBI patients. The data from this collaboration are anticipated to inform the development of Biosplice’s DYRK inhibitor class in the treatment of degenerative neurological conditions, including various … ovel neurology therapies, ranging from TBI to ALS to Alzheimer’s disease.” This award builds upon more than four years of scientific collaboration between Roskamp and Biosplice. Previous research conducted by Roskamp has demonstrated efficacy in TBI animal models with Biosplice’s first-generation DYRK inhibitors. About Roskamp: Since opening its
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Biosplice Presents Successful Structure and Pain Results --> Accessibility: Skip TopNav Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis Robust three-year X-ray results of medial joint space width (mJSW) and significant pain response in patients highlight the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis (OA) November 13, 2023 06:00 ET | Source: Biosplice Therapeutics, Inc. Biosplice Therapeutics
Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial December 15, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Biosplice Therapeutics, Inc. announced potential structure-modifying h … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biosplice Therapeutics | Sands Capital Job Board Sands Capital Portfolio Company Job Board Find a job at one of our innovative portfolio companies • jobs · • companies Search jobs Explore companies Join talent network Talent My job alerts Biosplice Therapeutics biosplice.com Locations San Diego, CA, USA · Liberty Station, San Diego, CA, USA industry Biotechnology · Health Care · Life Science Size 51 - 200 employees Stage Pre Seed founded in 2008 Socials LinkedIn Crunchbase Twitter About Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their